Prednisone

Generic Name: Prednisone

Brand Names: Deltasone, Rayos, Winpred

Drug Type: Small Molecule

Chemical Formula: C_₂₁H_₂₆O_₅

CAS Number: 53-03-2

Unique Ingredient Identifier: VB0R961HZT

Background: A synthetic anti-inflammatory glucocorticoid derived from cortisone. It is biologically inert and converted to prednisolone in the liver.

Prednisone was granted FDA approval on 21 February 1955.

Indication: Prednisone is indicated as an anti-inflammatory or immunosuppressive drug for allergic, dermatologic, gastrointestinal, hematologic, ophthalmologic, nervous system, renal, respiratory, rheumatologic, infectious, endocrine, or neoplastic conditions as well as in organ transplant.

Associated Conditions: Acne Vulgaris, Acute Exacerbation of Chronic Obstructive Pulmonary Disease, Acute Gouty Arthritis, Acute Leukemia, Aggressive Lymphoma, Allergic Bronchopulmonary Aspergillosis, Allergic Conjunctivitis (AC), Allergic Rhinitis (AR), Allergic corneal marginal ulcers, Alveolitis, Extrinsic Allergic, Ankylosing Spondylitis (AS), Aspiration Pneumonitis, Asthma, Atopic Dermatitis, Autoimmune Hepatitis, Bell's Palsy, Berylliosis, Bullous dermatitis herpetiformis, Chorioretinitis, Congenital Adrenal Hyperplasia (CAH), Congenital Hypoplastic Anemia, Contact Dermatitis, Disseminated tuberculosis, Drug hypersensitivity reaction, Edema of the cerebrum, Epicondylitis, Erythroblastopenia, Giant Cell Arteritis (GCA), Hypercalcemia of Malignancy, Idiopathic Pulmonary Fibrosis (IPF), Immune Thrombocytopenia (ITP), Iridocyclitis, Iritis, Keratitis, Leukemias, Loeffler's syndrome, Lymphoma, Meningitis caused by Mycobacterium Tuberculosis, Metastatic Castration-Resistant Prostate Cancer (mCRPC), Mycosis Fungoides (MF), Ocular Inflammation, Ophthalmia, Sympathetic, Optic Neuritis, Pain caused by Herpes zoster, Pemphigus, Pericarditis, Pneumocystis Jirovecii Pneumonia, Polymyalgia Rheumatica (PMR), Polymyositis, Posterior Uveitis, Primary adrenocortical insufficiency, Psoriatic Arthritis, Pure Red Cell Aplasia, Regional Enteritis, Relapsing Polychondritis, Rheumatoid Arthritis, Rheumatoid Arthritis, Juvenile, Secondary adrenocortical insufficiency, Secondary thrombocytopenia, Serum Sickness, Severe Seborrheic Dermatitis, Sjogren's Syndrome (SS), Solid Organ Transplant Rejection, Stevens-Johnson Syndrome, Systemic Lupus Erythematosus, Takayasu Arteritis, Thyroid Eye Disease, Thyroiditis, Thyrotoxicosis, Trichinosis, Ulcerative Colitis, Uveitis, Vasculitis, Acquired immune hemolytic anemia, Acute Bursitis, Acute Crohn's Disease (CD), Acute Multiple sclerosis exacerbation, Acute rheumatic carditis, Anterior eye segment inflammation, Exfoliative erythroderma, Fulminating Tuberculosis, Idiopathic Bronchiolitis obliterans with organizing pneumonia, Idiopathic eosinophilic pneumonias, Non-suppurative Thyroiditis, Severe Psoriasis, Subacute Bursitis, Symptomatic Sarcoidosis, Synovitis of osteoarthritis, Systemic Dermatomyositis, Varicella-zoster virus acute retinal necrosis

Associated Therapies: Palliative Treatment

Clinical Trials

Study of Oral Ixazomib in Combination With Melphalan and Prednisone in Participants With Newly Diagnosed Multiple Myeloma

Phase 1

Completed

Conditions: Multiple Myeloma

Interventions: Drug: Ixazomib
Drug: Melphalan
Drug: Prednisone

First Posted Date: 2011-04-14

Last Posted Date: 2018-01-23

Lead Sponsor: Millennium Pharmaceuticals, Inc.

Target Recruit Count: 61

Registration Number: NCT01335685

Everolimus, Rituximab, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Untreated Diffuse Large B-Cell Lymphoma

Phase 1

Completed

Conditions: Lymphoma

Interventions: Biological: rituximab
Drug: cyclophosphamide
Drug: doxorubicin hydrochloride
Drug: everolimus
Drug: prednisone
Drug: vincristine sulfate

First Posted Date: 2011-04-13

Last Posted Date: 2017-08-10

Lead Sponsor: Alliance for Clinical Trials in Oncology

Target Recruit Count: 26

Registration Number: NCT01334502

Locations: 🇺🇸
Mayo Clinic Cancer Center, Rochester, Minnesota, United States

A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM)

Phase 3

Completed

Conditions: Non-Hodgkin's Lymphoma

Interventions: Drug: Cyclophosphamide
Drug: Obinutuzumab
Drug: Doxorubicin
Drug: Vincristine
Drug: Prednisone
Drug: Bendamustine
Drug: Rituximab

First Posted Date: 2011-04-11

Last Posted Date: 2022-08-11

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 1401

Registration Number: NCT01332968

Locations: 🇨🇦
North York General Hospital, Toronto, Ontario, Canada
🇦🇺
St Vincent'S Hospital; Haematology, Fitzroy, Victoria, Australia
🇨🇦
Humber River Hospital, Toronto, Ontario, Canada

and more 180 locations

Safety & Efficacy of BCT197A2201 in COPD Patients Presenting With an Exacerbation

Phase 2

Completed

Conditions: Chronic Obstructive Pulmonary Disease

Interventions: Drug: BCT197
Drug: Prednisone placebo
Drug: BCT197 placebo
Drug: Prednisone

First Posted Date: 2011-04-08

Last Posted Date: 2023-03-21

Lead Sponsor: Mereo BioPharma

Target Recruit Count: 183

Registration Number: NCT01332097

Locations: 🇷🇺
Novartis Investigative Site, St. Petersburg, Russian Federation

Gene Therapy for Fanconi Anemia

Phase 1

Terminated

Conditions: Fanconi Anemia

Interventions: Procedure: Bone Marrow Aspiration
Biological: Filgrastim
Biological: Genetically Engineered Hematopoietic Stem Progenitor Cells
Other: Laboratory Biomarker Analysis
Procedure: Leukapheresis
Drug: Methylprednisolone
Drug: Plerixafor
Drug: Prednisone

First Posted Date: 2011-04-07

Last Posted Date: 2024-05-17

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 3

Registration Number: NCT01331018

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

Stage I/II Nasal NK Cell Lymphoma

Phase 1

Terminated

Conditions: Lymphoma

Interventions: Radiation: Radiation
Drug: Cyclophosphamide
Drug: Doxorubicin
Drug: Vincristine
Drug: Prednisone

First Posted Date: 2011-03-23

Last Posted Date: 2015-02-05

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 1

Registration Number: NCT01321008

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

A Phase 1 Study of Brentuximab Vedotin Given Sequentially and Combined With Multi-Agent Chemotherapy for CD30-Positive Mature T-Cell and NK-Cell Neoplasms

Phase 1

Completed

Conditions: Lymphoma, Large-Cell, Anaplastic
Lymphoma, NK-cell
Lymphoma, T-cell

Interventions: Drug: brentuximab vedotin
Drug: cyclophosphamide
Drug: prednisone
Drug: doxorubicin
Drug: vincristine

First Posted Date: 2011-03-07

Last Posted Date: 2017-06-28

Lead Sponsor: Seagen Inc.

Target Recruit Count: 39

Registration Number: NCT01309789

Locations: 🇺🇸
UAB Comprehensive Cancer Center, Birmingham, Alabama, United States
🇺🇸
City of Hope National Medical Center, Duarte, California, United States
🇺🇸
Stanford Cancer Center, Stanford, California, United States

and more 8 locations

S1014 Abiraterone Acetate in Treating Patients With Prostate Cancer Who Have Undergone Initial Hormone Therapy

Phase 2

Completed

Conditions: Prostate Cancer

Interventions: Drug: abiraterone acetate
Drug: Prednisone

First Posted Date: 2011-03-07

Last Posted Date: 2025-01-08

Lead Sponsor: SWOG Cancer Research Network

Target Recruit Count: 41

Registration Number: NCT01309672

Locations: 🇺🇸
Grant Medical Center Cancer Care, Columbus, Ohio, United States
🇺🇸
Sletten Cancer Institute at Benefis Healthcare, Great Falls, Montana, United States
🇺🇸
Kaiser Permanente Medical Center - Richmond, Richmond, California, United States

and more 202 locations

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Phase 3

Completed

Conditions: Prostate Cancer

Interventions: Drug: Cabazitaxel (XRP6258)
Drug: Docetaxel (XRP6976)
Drug: Prednisone

First Posted Date: 2011-03-04

Last Posted Date: 2019-06-05

Lead Sponsor: Sanofi

Target Recruit Count: 1168

Registration Number: NCT01308567

Locations: 🇫🇷
Investigational Site Number 250010, Besancon Cedex, France
🇺🇸
Investigational Site Number 840035, Jacksonville, Florida, United States
🇧🇾
Investigational Site Number 112001, Minsk, Belarus

and more 164 locations

A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA)

Phase 3

Terminated

Conditions: Diffuse Large B-Cell Lymphoma

Interventions: Drug: Rituximab
Drug: Obinutuzumab
Drug: Cyclophosphamide
Drug: Doxorubicin
Drug: Vincristine
Drug: Prednisone

First Posted Date: 2011-02-01

Last Posted Date: 2019-04-12

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 1418

Registration Number: NCT01287741

Locations: 🇨🇦
Humber River Hospital, Toronto, Ontario, Canada
🇺🇸
UCLA - School of Medicine; Division of Hematology/Oncology, Los Angeles, California, United States
🇵🇱
Uniwersyteckie Centrum Kliniczne; Klinika Hematologii i Transplantologii, Gdansk, Poland

and more 232 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy